SI2125779T1 - Polimorfi antagonista receptorja mglur5 - Google Patents

Polimorfi antagonista receptorja mglur5

Info

Publication number
SI2125779T1
SI2125779T1 SI200731792A SI200731792A SI2125779T1 SI 2125779 T1 SI2125779 T1 SI 2125779T1 SI 200731792 A SI200731792 A SI 200731792A SI 200731792 A SI200731792 A SI 200731792A SI 2125779 T1 SI2125779 T1 SI 2125779T1
Authority
SI
Slovenia
Prior art keywords
polymorphs
receptor antagonist
mglur5 receptor
mglur5
antagonist
Prior art date
Application number
SI200731792A
Other languages
English (en)
Inventor
Thomas P. Cleary
Alexander Glomme
Olaf Grassmann
Shan-Ming Kuang
Roland Meier
Doreen Miller
Regina Moog
Franziska E. Rohrer
Jason Yang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2125779(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2125779T1 publication Critical patent/SI2125779T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200731792A 2006-12-21 2007-12-11 Polimorfi antagonista receptorja mglur5 SI2125779T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87639806P 2006-12-21 2006-12-21
EP07857408.4A EP2125779B1 (en) 2006-12-21 2007-12-11 Polymorphs of a mglur5 receptor antagonist
PCT/EP2007/063721 WO2008074697A1 (en) 2006-12-21 2007-12-11 Polymorphs of a mglur5 receptor antagonist

Publications (1)

Publication Number Publication Date
SI2125779T1 true SI2125779T1 (sl) 2016-07-29

Family

ID=39186951

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731792A SI2125779T1 (sl) 2006-12-21 2007-12-11 Polimorfi antagonista receptorja mglur5

Country Status (33)

Country Link
US (2) US8063076B2 (sl)
EP (1) EP2125779B1 (sl)
JP (1) JP5405311B2 (sl)
KR (1) KR101148580B1 (sl)
CN (1) CN101568531B (sl)
AR (1) AR064654A1 (sl)
AU (1) AU2007336369B2 (sl)
BR (1) BRPI0720954A2 (sl)
CA (1) CA2673444C (sl)
CL (1) CL2007003695A1 (sl)
CO (1) CO6210731A2 (sl)
CY (1) CY1117810T1 (sl)
DK (1) DK2125779T3 (sl)
EC (1) ECSP099431A (sl)
ES (1) ES2577391T3 (sl)
HR (1) HRP20160950T1 (sl)
HU (1) HUE029324T2 (sl)
IL (1) IL199181A (sl)
MA (1) MA31008B1 (sl)
MX (1) MX2009006694A (sl)
MY (1) MY148217A (sl)
NO (1) NO342451B1 (sl)
NZ (1) NZ577440A (sl)
PE (1) PE20081484A1 (sl)
PL (1) PL2125779T3 (sl)
PT (1) PT2125779T (sl)
RS (1) RS54853B1 (sl)
RU (1) RU2460728C2 (sl)
SI (1) SI2125779T1 (sl)
TW (1) TWI347320B (sl)
UA (1) UA96970C2 (sl)
WO (1) WO2008074697A1 (sl)
ZA (1) ZA200904289B (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54853B1 (sr) 2006-12-21 2016-10-31 Hoffmann La Roche Polimorfi antagonista mglur5 receptora
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
CN103561740A (zh) 2011-03-18 2014-02-05 诺瓦提斯公司 用于帕金森病中多巴胺诱导的运动障碍的α7烟碱性乙酰胆碱受体活化剂和mGluR5拮抗剂的组合
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
GB201317022D0 (en) * 2013-09-25 2013-11-06 Addex Pharmaceuticals Sa Polymorphs
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
EP4161512A1 (en) 2020-06-05 2023-04-12 Noema Pharma AG Methods of treatment of tuberous sclerosis complex
MX2023001288A (es) * 2020-07-30 2023-04-28 Noema Pharma Ag Metodos de tratamiento de la neuralgia del trigemino.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
EP0079312A3 (de) 1981-11-11 1984-04-25 Ciba-Geigy Ag Heterocyclische Acetylenverbindungen
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
RU2099330C1 (ru) 1989-06-30 1997-12-20 Е.И.Дюпон Де Немур Энд Компани Замещенные имидазолы или их фармацевтически приемлемые соли и фармацевтическая композиция
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
BR9811933A (pt) 1997-08-14 2000-09-05 Hoffmann La Roche Vinil éteres heterocìclicos contra distúrbios neurológicos
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
DE60142236D1 (de) 2000-07-24 2010-07-08 Krenitsky Pharmaceuticals Inc Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
IL155999A0 (en) 2000-12-04 2003-12-23 Hoffmann La Roche Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US20040259917A1 (en) 2001-12-19 2004-12-23 Cosford Nicholas D.P. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
AU2005250101B2 (en) * 2004-06-01 2011-08-25 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mGlu5 receptor antagonists
RS54853B1 (sr) 2006-12-21 2016-10-31 Hoffmann La Roche Polimorfi antagonista mglur5 receptora

Also Published As

Publication number Publication date
ZA200904289B (en) 2010-04-28
CA2673444A1 (en) 2008-06-26
JP2010513378A (ja) 2010-04-30
RS54853B1 (sr) 2016-10-31
IL199181A (en) 2016-02-29
PE20081484A1 (es) 2008-10-18
TW200833679A (en) 2008-08-16
AU2007336369A1 (en) 2008-06-26
CN101568531B (zh) 2013-11-13
EP2125779B1 (en) 2016-04-27
CN101568531A (zh) 2009-10-28
US8063076B2 (en) 2011-11-22
MY148217A (en) 2013-03-29
RU2009123135A (ru) 2011-01-27
EP2125779A1 (en) 2009-12-02
HUE029324T2 (en) 2017-02-28
RU2460728C2 (ru) 2012-09-10
MX2009006694A (es) 2009-06-30
NO342451B1 (no) 2018-05-22
US8329912B2 (en) 2012-12-11
ECSP099431A (es) 2009-07-31
CY1117810T1 (el) 2017-05-17
DK2125779T3 (en) 2016-07-04
MA31008B1 (fr) 2009-12-01
TWI347320B (en) 2011-08-21
KR20090081026A (ko) 2009-07-27
WO2008074697A1 (en) 2008-06-26
HRP20160950T1 (hr) 2016-10-07
ES2577391T3 (es) 2016-07-14
UA96970C2 (en) 2011-12-26
CA2673444C (en) 2015-01-20
NO20092357L (no) 2009-07-15
PT2125779T (pt) 2016-07-19
NZ577440A (en) 2011-12-22
KR101148580B1 (ko) 2012-05-24
CO6210731A2 (es) 2010-10-20
BRPI0720954A2 (pt) 2014-03-18
US20120035222A1 (en) 2012-02-09
US20080312288A1 (en) 2008-12-18
AR064654A1 (es) 2009-04-15
AU2007336369B2 (en) 2013-01-17
JP5405311B2 (ja) 2014-02-05
PL2125779T3 (pl) 2016-11-30
CL2007003695A1 (es) 2008-07-04

Similar Documents

Publication Publication Date Title
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
HK1245264A1 (zh) 多晶型
EP2034832A4 (en) IL-8 RECEPTOR ANTAGONIST
HRP20151108T1 (en) Nogo receptor antagonists
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
ZA200808358B (en) IL-8 receptor antagonists
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ZA201006830B (en) Heterocyclic compounds as adenosine receptor antagonist
EP1935874A4 (en) ANTAGONIST OF THE RECEIVER OF S1P3
IL194700A0 (en) Il-8 receptor antagonists
EP2099300A4 (en) IL-8 RECEPTOR ANTAGONISTS
ZA200903271B (en) Solid dispersion of a neurokinin antagonist
EP2191830A4 (en) SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST
IL195807A0 (en) Cgrp receptor antagonists
ZA200808766B (en) Nitrated heterocyclic compounds as endothelin receptor antagonist
HK1206363A1 (zh) μ-阿片受體肽的有益鹽
EP2153736A4 (en) NEW LEUKOTRIEN RECEPTOR ANTAGONIST
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
EP2089019A4 (en) POLYMORPHS OF AN ANTAGONIST OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
EP2057144A4 (en) NEW POLYMORPHIC FROM RIMONABANT
GB0525029D0 (en) Receptor Antagonist
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
ZA200903609B (en) Motilide polymorphs
GB0701632D0 (en) MET receptor antagonists
GB0623853D0 (en) Receptor